News Focus
News Focus
Followers 479
Posts 61844
Boards Moderated 15
Alias Born 09/20/2001

Re: F1ash post# 125643

Saturday, 10/21/2017 12:11:40 PM

Saturday, October 21, 2017 12:11:40 PM

Post# of 517287
Complete lack of correlation and misrepresentation of data...

Different MOA


Azeliragon is an oral, small-molecule inhibitor of RAGE. This cell-surface receptor of the immunoglobulin superfamily is expressed on multiple cell types. RAGE binds advanced glycation end products (AGEs); these are modified forms of lipids and proteins that become glycated when exposed to sugars. AGEs form during normal aging and in higher amounts in patients with diabetes. When bound to their receptors, AGEs cause inflammation and oxidative damage. RAGE also binds Aß (Yan et al., 1996), and has been reported to mediate toxic effects of Aß oligomers in neurons (see Mar 2008 news). RAGE is upregulated in astrocytes and microglia in the hippocampi of people with AD (Lue et al., 2005) and is thought to mediate amyloid transport into the brain. The RAGE antagonist azeliragon blocks this interaction; hence the rationale is that it could provide a combined treatment effect across glial inflammatory and amyloid-related processes. In preclinical studies, the compound decreased brain Aß load in transgenic mice and improved their performance on behavioral assays.



Lack of relevance per safety issues - some people have been on 2-73 for close to two years now.



In 2007, Pfizer and the National Institute on Aging jointly funded a larger, 18-month Phase 2 trial run via the Alzheimer's Disease Cooperative Study (ADCS). This trial recruited 399 people with mild to moderate AD and evaluated the same doses for safety and efficacy as measured by the ADAS-cog. The higher dose was dropped after a six-month interim analysis flagged both safety signals and faster deterioration. The low dose was halted before its intended conclusion following a futility analysis that indicated no benefit; however, follow-up examination conducted after treatment was suspended did suggest a possible belated clinical benefit for the low dose (see Nov 2011 conference news story).



As I said, the second trial was pre-alzheimer's.

That post was 100% obfuscation.





In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News